New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
09:13 EDTKOOLThermogenesis, TotipotentRX report significant Phase Ib trial results
ThermoGenesis and TotipotentRX announce their co-sponsored Phase Ib clinical trial safety and efficacy results treating no-option patients suffering from critical limb ischemia with Totipotent's Critical Limb Ischemia Rapid Stem cell Therapy, or CLIRST, treatment. The trial achieved both its primary safety and secondary efficacy endpoints at 12 months, achieving statistical significance in five key areas including, major amputation free survival rates, both resting and walking pain reduction, improved walking distance, open wound healing and vasculogenesis in the treated leg. Furthermore, there were no serious adverse events determined to be related to the therapy.
News For KOOL From The Last 14 Days
Check below for free stories on KOOL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
09:21 EDTKOOLCesca Therapeutics restructures sales and marketing section
Cesca Therapeutics announced the restructuring of its sales, marketing and technical support organization and the appointment of Tim Lee as Director of International Sales. The restructuring will realign Hal Baker from his current role as VP of Commercial Operations, to an external consulting and advisory role, which will ensure an orderly transition of his existing responsibilities with specific attention given to cord blood sales and marketing initiatives. In the newly formed role, Director of International Sales, Mr. Lee's primary focus will be to lead global cord blood product sales and services. Mr. Lee has been involved with the medical and therapeutic research instrument industry for over 20 years.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use